Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Baloxavir · 1 trial · 4 indications
The primary outcome is time to recovery (defined as the first instance that a participant report feeling fully recovered)
| Arm | Type | Description |
|---|---|---|
| Acute Influenza A/B - Matched placebo for Baloxavir | PLACEBO_COMPARATOR | Usual Care (i.e., supportive care and symptom relief). Matching control placebo for Baloxavir - a single matching dose. |
| Acute Influenza A/B - Baloxavir | EXPERIMENTAL | The adaptative platform trial will assess therapeutics for influenza A/B in out-patient setting. Interventions include: Baloxavir. Baloxavir dose: if weight \<80 kg: one 40 mg dose for 1 day; if weight ≥80kg, one 80 mg dose for one day. |
| Name | Type | Description |
|---|---|---|
| Baloxavir | DRUG | This is a sub-protocol within the TreatResp adaptive platform trial to compare the clinical and cost-effectiveness of Baloxavir, a single 40mg or 80 mg tablet based on patient weight, to a matching placebo among non-hospitalized patients with mild to moderate influenza A/B. This sub-protocol is part of the influenza domain within TreatResp. |
| Placebo Control | DRUG | Matching placebo for Baloxavir |
Inclusion Criteria: * 18 years or older * A positive test (PCR or RAT) for one of the pathogens included in the trial's domains (influenza A/B, or other future specified respiratory pathogens), * Enrolled within 5 days of symptoms onset. However, this window may vary depending on the domain or spec...